Sabadinine: A Potential Non-Peptide Anti-Severe Acute-Respiratory-Syndrome Agent Identified using Structure-Aided Design

Journal of Medicinal Chemistry

Volumn 47, Issue 5, 2004, Pages 1079-1080

  Toney, Jeffrey H ^a   Navas Martín, Sonia ^b   Weiss, Susan R ^b   Koeller, Andreas ^a  

^a MONTCLAIR STATE UNIVERSITY   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; NATURAL PRODUCT; PROTEINASE; SABADININE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CORONAVIRUS; CRYSTAL STRUCTURE; DRUG ISOLATION; DRUG TARGETING; ENZYME ACTIVE SITE; HERBAL MEDICINE; NONHUMAN; PROTEIN DEGRADATION; SEVERE ACUTE RESPIRATORY SYNDROME; STRUCTURE ACTIVITY RELATION; VIRUS REPLICATION;

ANTIVIRAL AGENTS; BINDING SITES; CELLS, CULTURED; CEVANES; CORONAVIRUS; CORONAVIRUS INFECTIONS; CYSTEINE ENDOPEPTIDASES; CYSTEINE PROTEINASE INHIBITORS; DATABASES, FACTUAL; HUMANS; MODELS, MOLECULAR; MURINE HEPATITIS VIRUS;

EID: 1242318794     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm034137m     Document Type: Article

References (9)

1. Donnelly, C. A.; Ghani, A. C.; Leung, G. M.; Hedley, A. J.; Fraser, C.; et al. Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong. Lancet 2003, 361, 1761-1766.
2. Drosten, C.; Gunther, S.; Preiser, W.; van der Werf, S.; Brodt, H. R.; et al. Identification of a novel coronavirus in patients with severe acute respiratory syndrome. N. Engl. J. Med. 2003, 348, 1967-1976.
3. Anand, K.; Ziebuhr, J.; Wadhwani, P.; Mesters, J. R.; Hilgenfeld, R. Coronavirus main proteinase (3CLpro) structure: basis for design of anti-SARS drugs. Science 2003, 300, 1763-1767.
4. Morris, G. M.; Goodsell, D. S.; Huey, R.; Olson, A. J. Distributed automated docking of flexible ligands to proteins: parallel applications of AutoDock 2.4. J. Comput.-Aided Mol. Des. 1996, 10, 293-304.
5. Navas, S.; Weiss, S. R. Murine coronavirus-induced hepatitis: JHM genetic background eliminates A59 spike-determined hepatotropism. J. Virol. 2003, 77, 4972-4978.
6. Navas-Martin, S.; Weiss, S. R. SARS: lessons learned from other Coronaviruses. Viral Immunol. 2004, 16, 461-474.
7. Xiong, B.; Gui, C. S.; Xu, X. Y.; Luo, C.; Chen, J.; et al. A 3D model of SARS_CoV 3CL proteinase and its inhibitors design by virtual screening. Acta Pharmacol. Sin. 2003, 24, 497-504.
8. Lee, V. S.; Wittayanarakut, K.; Remsungnen, T.; Parasuk, V.; Sompornpisut, P.; et al. Structure and Dynamics of SARS Coronavirus Proteinase: The Primary Key to the Designing and Screening for Anti-SARS Drugs. Science Asia 2003, 29, 181-188.
9. Sayre, L. E. Sabadilla. Cevadilla. A Manual of Organic Materia and Pharmacognosy; P. Blakiston's Son & Co.: Philadelphia, PA, 1917; pp 60-61.